TB Drug Development Gerald J. Siuta, Ph.D. Business Development May 3, 2007.
-
Upload
amelia-holloway -
Category
Documents
-
view
218 -
download
0
Transcript of TB Drug Development Gerald J. Siuta, Ph.D. Business Development May 3, 2007.
![Page 1: TB Drug Development Gerald J. Siuta, Ph.D. Business Development May 3, 2007.](https://reader033.fdocuments.in/reader033/viewer/2022061305/55140f93550346dd488b4fd9/html5/thumbnails/1.jpg)
TB Drug DevelopmentGerald J. Siuta, Ph.D.Business Development
May 3, 2007
![Page 2: TB Drug Development Gerald J. Siuta, Ph.D. Business Development May 3, 2007.](https://reader033.fdocuments.in/reader033/viewer/2022061305/55140f93550346dd488b4fd9/html5/thumbnails/2.jpg)
Tuberculosis One-third of the world’s population is infected
with Mycobacterium tuberculosis – 2 billion people
8-9 million develop active disease annually 2 million deaths occur each year
– 1 person dies every 15 seconds 400,000 cases of MDR-TB each year Leading cause of death in HIV-positive people
– 12 Million people are TB/HIV co-infected
![Page 3: TB Drug Development Gerald J. Siuta, Ph.D. Business Development May 3, 2007.](https://reader033.fdocuments.in/reader033/viewer/2022061305/55140f93550346dd488b4fd9/html5/thumbnails/3.jpg)
Current TB Drug Therapy Active TB
– Standard therapy – 4 drugs (isoniazid, rifampin, pyrazinamide & ethambutol) for 2 months, followed by isoniazid and rifampin for 4 months
Latent TB– Standard therapy – isoniazid for 9 months
Multi-Drug Resistant TB (MDR-TB)– Prolonged therapy, few available drugs, poorly tolerated
and difficult to administer TB/HIV Co-Infection
– Drug interactions with antiretroviral agents - simultaneous therapy difficult
![Page 4: TB Drug Development Gerald J. Siuta, Ph.D. Business Development May 3, 2007.](https://reader033.fdocuments.in/reader033/viewer/2022061305/55140f93550346dd488b4fd9/html5/thumbnails/4.jpg)
The Need for New TB Drugs
Complex 6-9 months treatment with a 4 drug combination regimen
No new anti-TB drug in over 30 years TB/HIV co-infections fueling each other MDR-TB is on the rise Unattractive market for private sector No capitalization of public sector research
![Page 5: TB Drug Development Gerald J. Siuta, Ph.D. Business Development May 3, 2007.](https://reader033.fdocuments.in/reader033/viewer/2022061305/55140f93550346dd488b4fd9/html5/thumbnails/5.jpg)
History of the TB Alliance
Cape Town Declaration – Feb 2000– Hosts: Rockefeller Foundation & MRC S. Africa– Over 120 organizations (health, science, philanthropy
and private industry)
Results
– Support goals of Stop TB Initiative– Create Scientific Blueprint– Develop Pharmacoeconomic Analysis
Build a global alliance forTB drug development
![Page 6: TB Drug Development Gerald J. Siuta, Ph.D. Business Development May 3, 2007.](https://reader033.fdocuments.in/reader033/viewer/2022061305/55140f93550346dd488b4fd9/html5/thumbnails/6.jpg)
The TB Alliance
International Public-Private Partnership Non-profit organization Based in New York City, Brussels and
Cape Town Entrepreneurial, virtual R&D approach
– Out-source R&D to public or private partners Pro-active fundraising
![Page 7: TB Drug Development Gerald J. Siuta, Ph.D. Business Development May 3, 2007.](https://reader033.fdocuments.in/reader033/viewer/2022061305/55140f93550346dd488b4fd9/html5/thumbnails/7.jpg)
Public-Private Partnership
An organization that pursues a social mission by employing the best
practices of the private sector and drawing upon resources from the
public and private realms
![Page 8: TB Drug Development Gerald J. Siuta, Ph.D. Business Development May 3, 2007.](https://reader033.fdocuments.in/reader033/viewer/2022061305/55140f93550346dd488b4fd9/html5/thumbnails/8.jpg)
TB Alliance Mission
To ensure equitable access to a faster tuberculosis cure
that will advance global health and prosperity
![Page 9: TB Drug Development Gerald J. Siuta, Ph.D. Business Development May 3, 2007.](https://reader033.fdocuments.in/reader033/viewer/2022061305/55140f93550346dd488b4fd9/html5/thumbnails/9.jpg)
Profile of New TB Drug
Shorten the duration of TB treatment or otherwise simplify its completion
Be effective against multi-drug resistant tuberculosis (MDR-TB)
Improve the treatment of latent TB Be compatible with HIV treatment
![Page 10: TB Drug Development Gerald J. Siuta, Ph.D. Business Development May 3, 2007.](https://reader033.fdocuments.in/reader033/viewer/2022061305/55140f93550346dd488b4fd9/html5/thumbnails/10.jpg)
Goals and Objectives
Develop an entirely new therapeutic regimen that will shorten or simplify the treatment of tuberculosis
Coordinate and catalyze TB drug development activities worldwide
Ensure Affordability, Adoption and Access (AAA Strategy)
![Page 11: TB Drug Development Gerald J. Siuta, Ph.D. Business Development May 3, 2007.](https://reader033.fdocuments.in/reader033/viewer/2022061305/55140f93550346dd488b4fd9/html5/thumbnails/11.jpg)
AAA Strategy
Affordability– Appropriate pricing in developing countries
Adoption– Ensure that new drugs are incorporated into
existing treatment programs Access
– Procurement and distribution to those patients who need them most
![Page 12: TB Drug Development Gerald J. Siuta, Ph.D. Business Development May 3, 2007.](https://reader033.fdocuments.in/reader033/viewer/2022061305/55140f93550346dd488b4fd9/html5/thumbnails/12.jpg)
Financial Support
Bill and Melinda Gates Foundation Rockefeller Foundation Netherlands Ministry for Development
Cooperation United States Agency for International
Development (USAID) Governments of Great Britain and Ireland
![Page 13: TB Drug Development Gerald J. Siuta, Ph.D. Business Development May 3, 2007.](https://reader033.fdocuments.in/reader033/viewer/2022061305/55140f93550346dd488b4fd9/html5/thumbnails/13.jpg)
Types of Deals/Agreements
Licensing Sponsored Projects Outsourcing/Contracts Co-Development Co-Investments Partnerships Others
![Page 14: TB Drug Development Gerald J. Siuta, Ph.D. Business Development May 3, 2007.](https://reader033.fdocuments.in/reader033/viewer/2022061305/55140f93550346dd488b4fd9/html5/thumbnails/14.jpg)
TB Alliance PortfolioDiscovery
Co
mp
ou
nd
s, A
nal
og
s an
d D
eriv
ativ
es
Nitroimidazole Analogs (University of Auckland, Novartis ITD, NIAID)
Quinolones(KRICT/Yonsei University)
Multi-Functional Molecules(Cumbre)
Bacterial Topoisomerase Inhibitors(GlaxoSmithKline)
InhA Inhibitors(GlaxoSmithKline)
Malate Synthase Inhibitors(GlaxoSmithKline/Texas A&M)
Nitroimidazole PA-824 (Chiron/Novartis)
Preclinical Clinical
Active TB Alliance program
TB Alliance in discussion
Focused Screening – Two Projects(GlaxoSmithKline)
Pleuromutilins(GlaxoSmithKline)
Moxifloxacin (Bayer HealthCare AG)
Proteasome Inhibitors(Cornell University)
New Targets(University of Pennsylvania)
Riminophenazines(Institute of Materia Medica)
![Page 15: TB Drug Development Gerald J. Siuta, Ph.D. Business Development May 3, 2007.](https://reader033.fdocuments.in/reader033/viewer/2022061305/55140f93550346dd488b4fd9/html5/thumbnails/15.jpg)
Chiron
Novel anti-TB compound (PA-824) Discovered by Pathogenesis, Inc. Exclusive worldwide license Defined scientific milestones Grant-back option Manufacturing rights No royalties in high endemic countries
![Page 16: TB Drug Development Gerald J. Siuta, Ph.D. Business Development May 3, 2007.](https://reader033.fdocuments.in/reader033/viewer/2022061305/55140f93550346dd488b4fd9/html5/thumbnails/16.jpg)
PA-824
Novel nitroimidazole Potent activity against both active and
slow growing M.tb. Possesses both bactericidal and sterilizing
activity Phase I clinical trials began June 3, 2005
– Preclinical development completed in 3 years
![Page 17: TB Drug Development Gerald J. Siuta, Ph.D. Business Development May 3, 2007.](https://reader033.fdocuments.in/reader033/viewer/2022061305/55140f93550346dd488b4fd9/html5/thumbnails/17.jpg)
University of Auckland Synthesis of PA-824 analogs Joint program with:
– Novartis Institute of Tropical Diseases (Singapore)
– National Institute of Allergy and Infectious Diseases
Aims to discover new nitroimidazopyrans that may have improved profiles over PA-824
![Page 18: TB Drug Development Gerald J. Siuta, Ph.D. Business Development May 3, 2007.](https://reader033.fdocuments.in/reader033/viewer/2022061305/55140f93550346dd488b4fd9/html5/thumbnails/18.jpg)
GlaxoSmithKline
Joint drug discovery program at GSK’s Diseases of the Developing World facility in Tres Cantos, Spain
Four individual projects:– Bacterial topoisomerase inhibitors– InhA inhibitors– Pleuromutilins– Focused screening (two projects)
![Page 19: TB Drug Development Gerald J. Siuta, Ph.D. Business Development May 3, 2007.](https://reader033.fdocuments.in/reader033/viewer/2022061305/55140f93550346dd488b4fd9/html5/thumbnails/19.jpg)
Korea Research Institute of Chemical Technology (KRICT)
Daejeon, South Korea Three year research funding
– Quinolones, pyridones & quinolizines Chemical synthesis at KRICT In vitro and in vivo biological testing at
Yonsei University College of Medicine in Seoul, South Korea
Clinical compound selection in progress
![Page 20: TB Drug Development Gerald J. Siuta, Ph.D. Business Development May 3, 2007.](https://reader033.fdocuments.in/reader033/viewer/2022061305/55140f93550346dd488b4fd9/html5/thumbnails/20.jpg)
Cumbre Pharmaceuticals
Joint program on the design, synthesis and optimization of two different classes of multi-functional antibiotics
The TB Alliance will have exclusive rights to these compounds for the treatment of tuberculosis and other neglected diseases
Cumbre will retain the rights to pursue the compounds for use in other infectious diseases
![Page 21: TB Drug Development Gerald J. Siuta, Ph.D. Business Development May 3, 2007.](https://reader033.fdocuments.in/reader033/viewer/2022061305/55140f93550346dd488b4fd9/html5/thumbnails/21.jpg)
Institute of Materia Medica Member of the Chinese Academy of Medical Sciences
that is one of the primary institutions for drug research in China
Joint research partnership for the design, synthesis and evaluation of a class of compounds known as riminophenazines– Originally discovered to be active against TB in the 1950s– Has not been used due to side effect profile
The collaboration will utilize IMM's expertise and integrated capabilities in chemistry, pharmacology and manufacture
![Page 22: TB Drug Development Gerald J. Siuta, Ph.D. Business Development May 3, 2007.](https://reader033.fdocuments.in/reader033/viewer/2022061305/55140f93550346dd488b4fd9/html5/thumbnails/22.jpg)
The TB Alliance-BayerMoxifloxacin Deal
![Page 23: TB Drug Development Gerald J. Siuta, Ph.D. Business Development May 3, 2007.](https://reader033.fdocuments.in/reader033/viewer/2022061305/55140f93550346dd488b4fd9/html5/thumbnails/23.jpg)
Moxifloxacin
Fluoroquinolone antibiotic Orally active Once-a-day dosage Approved in 104 countries for the
treatment of bacterial respiratory and skin infections
![Page 24: TB Drug Development Gerald J. Siuta, Ph.D. Business Development May 3, 2007.](https://reader033.fdocuments.in/reader033/viewer/2022061305/55140f93550346dd488b4fd9/html5/thumbnails/24.jpg)
Moxifloxacin for TB
Novel mechanism of action: kills M.tb. by inhibition of DNA gyrase
In vivo studies showed moxifloxacin reduced treatment time by two months when substituted for isoniazid
Safe to use with antiretroviral agents since it is not metabolized by the cytochrome P-450 enzyme system
![Page 25: TB Drug Development Gerald J. Siuta, Ph.D. Business Development May 3, 2007.](https://reader033.fdocuments.in/reader033/viewer/2022061305/55140f93550346dd488b4fd9/html5/thumbnails/25.jpg)
October 18, 2005
TB Alliance and Bayer HealthCare announced a partnership to coordinate a global clinical trial program to study
the potential of moxifloxacin to shorten the standard six-month treatment of TB
![Page 26: TB Drug Development Gerald J. Siuta, Ph.D. Business Development May 3, 2007.](https://reader033.fdocuments.in/reader033/viewer/2022061305/55140f93550346dd488b4fd9/html5/thumbnails/26.jpg)
The Partnership
Clinically assess the efficacy and safety of moxifloxacin as a front-line agent for the treatment of TB
If clinical trials are successful, register moxifloxacin for a TB indication
Committed to making the product affordable and accessible to patients in the developing world
![Page 27: TB Drug Development Gerald J. Siuta, Ph.D. Business Development May 3, 2007.](https://reader033.fdocuments.in/reader033/viewer/2022061305/55140f93550346dd488b4fd9/html5/thumbnails/27.jpg)
Moxifloxacin Clinical Trials
Phase II program will evaluate whether substitution of moxifloxacin for one of the standard TB drugs (isoniazid or ethambutol) eliminates TB infection faster than current standard therapy
Trials to be run in Brazil, Canada, South Africa, Spain, Tanzania, Uganda, the United States and Zambia
Nearly 2,500 TB patients are being enrolled
![Page 28: TB Drug Development Gerald J. Siuta, Ph.D. Business Development May 3, 2007.](https://reader033.fdocuments.in/reader033/viewer/2022061305/55140f93550346dd488b4fd9/html5/thumbnails/28.jpg)
Bayer Commitments
Donate moxifloxacin for each clinical trial site
Cover costs of regulatory filings Provide moxifloxacin at an affordable price
for patients with TB in the developing world
![Page 29: TB Drug Development Gerald J. Siuta, Ph.D. Business Development May 3, 2007.](https://reader033.fdocuments.in/reader033/viewer/2022061305/55140f93550346dd488b4fd9/html5/thumbnails/29.jpg)
TB Alliance Commitments
Coordinate and help cover the costs of the clinical trials
Ensure coordination of information and results towards the goal of registration
Leverage substantial support from:– U.S. Centers for Disease Control and Prevention (CDC)– Orphan Products Development Center of the U.S. Food &
Drug Administration– European and Developing Countries Clinical Trials
Partnership (EDCTP)
![Page 30: TB Drug Development Gerald J. Siuta, Ph.D. Business Development May 3, 2007.](https://reader033.fdocuments.in/reader033/viewer/2022061305/55140f93550346dd488b4fd9/html5/thumbnails/30.jpg)
Special Recognition
![Page 31: TB Drug Development Gerald J. Siuta, Ph.D. Business Development May 3, 2007.](https://reader033.fdocuments.in/reader033/viewer/2022061305/55140f93550346dd488b4fd9/html5/thumbnails/31.jpg)
Licensing Executives Society
On September 13, 2006, the Licensing Executives Society Industry/University and Government
Laboratory Transactions Industry Sector presented the TB Alliance and Bayer its Deals of Distinction
Award which recognizes worthy transactions involving licensing and transfer of intellectual property and promote creative and innovative
solutions to business issues
![Page 32: TB Drug Development Gerald J. Siuta, Ph.D. Business Development May 3, 2007.](https://reader033.fdocuments.in/reader033/viewer/2022061305/55140f93550346dd488b4fd9/html5/thumbnails/32.jpg)
Scrip – World Pharmaceutical News
The TB Alliance-Bayer deal was also one of six finalists for the Scrip 2006 Best Partnership
Alliance Award which recognizes the importance of partnerships involving pharmaceutical and/or
biotech companies, focusing on deals that require strong strategic input from both partners, are
mutually beneficial to both parties, hold promise to address an unmet medical need and demonstrate
strategic potential as well as an innovative business model
![Page 33: TB Drug Development Gerald J. Siuta, Ph.D. Business Development May 3, 2007.](https://reader033.fdocuments.in/reader033/viewer/2022061305/55140f93550346dd488b4fd9/html5/thumbnails/33.jpg)
Global Alliance for TBDrug Development
www.tballiance.org